Skip to content
Open access

Probiotic spore‐based bioresponsive drug delivery for reversing inflammatory bowel disease and its associated anxiety and depression

Sep 2026 · BMEMat · 0 citations · 47 references

Abstract

Patients with inflammatory bowel disease (IBD) often exhibit gut microbiota dysbiosis and are predisposed to psychiatric disorders such as anxiety and depression. Consequently, developing novel oral probiotic therapies to address intestinal inflammation, microbiota dysbiosis, and psychiatric comorbidities is essential for managing IBD. Here, we propose a probiotic spore‐based bioresponsive system (BCS‐Que@ApNPs) fabricated by thioketone linkage of Quercetin‐loaded Antheraea pernyi (AP) silk fibroin nanoparticles (Que@ApNPs) to the Bacillus coagulans spores (BCS). The AP silk fibroin with arginine‐glycine‐aspartate (RGD) tripeptides in Que@ApNPs nanoparticles is critical for bioresponsive targeting Quercetin (Que) delivery to the inflamed intestinal epithelium. BCS could effectively shield probiotics from gastric acid‐induced degradation, maintaining their bioactivity in the intestinal tract, where they modulate the gut microbiota and preserve the integrity of the intestinal barrier. Notably, BCS‐Que@ApNPs can inhibit neuroinflammation and enhance hippocampal neural plasticity in the IBD mice model. Additionally, behavioral test results reveal that BCS‐Que@ApNPs alleviate IBD‐associated anxiety and depressive behaviors. This work provides a bioresponsive probiotic drug hybrid delivery system, highlighting a gut‐brain axis intervention therapeutic strategy for individuals diagnosed with IBD and its associated anxiety and depression.

Read PDF

Similar papers

#protein folding Open access Sep 2026

Multifunctional Zinc Glycyrrhizinate‐Integrated Gel for Enhanced Probiotic Delivery and Alleviation of Acute and Spontaneous Colitis

In both dextran sulfate sodium‐induced colitis and IL‐10‐deficient spontaneous colitis mouse models, L. reuteri@ZGM persistently scavenged ROS, effectively reduced pro‐inflammatory cytokine levels, restored the expression of tight junction‐associated proteins and intestinal barrier function, enhanced probiotic coloniza...

Meng-Yun Peng, Xiao-Chun Chen, Wei Li et al. · 0 citations
Review Open access Sep 2026

Probiotic-Derived Extracellular Vesicles as Potential Nano-Immunotherapeutic Platforms in IBD: A Clinician’s Perspective

A comprehensive overview of probiotic-derived EVs, including their biogenesis, classification, and molecular composition, is provided, with a focus on barrier regulation, immune modulation, and microbial homeostasis in IBD.

H. Jeon, A. Choe, Seong-Eun Kim · 0 citations
Sep 2026

Engineered Calprotectin-Responsive Probiotics for Inflammatory Bowel Disease Treatment.

Inflammatory bowel disease (IBD) is a complex intestinal disorder for which effective treatment options remain limited. The modulation of gut microbiota balance using probiotics holds promise as a therapeutic approach to restore intestinal microenvironment homeostasis. However, the clinical translation of conventional...

Fan Yang, Li-Na He, Xiang Lin et al. · 0 citations
Review Oct 2026

Curcumin in inflammatory bowel disease: highlighting gut microbiota-metabolite-host interactions.

Inflammatory bowel disease (IBD) is driven by a complex interplay among epithelial barrier breakdown, immune dysregulation, microbial dysbiosis, and redox imbalance. Curcumin, a major curcuminoid from turmeric (Curcuma longa L.) and a widely used food ingredient, has attracted sustained interest as a dietary bioactive...

J. Pu, Ying-Lin Ding, Guo Chen et al. · 1 citation
Review Oct 2026

Recent advances in antioxidant nanozymes for the treatment of inflammatory bowel disease.

To overcome biopharmaceutical bottlenecks, an overview of nanozyme-based intelligent delivery platforms tailored for the inflamed gut are provided, covering endogenous/exogenous stimuli-responsive, biomimetic, and microbiota-mediated systems.

Zuo-Yi Shen, Shi-Qiao Rui, Jing-Qi Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.